BUY Aurobindo Pharma — Prakash Gaba, 10 Aug 2026

BUYAurobindo Pharma

Aurobindo Pharma share price target & all analyst calls

byPrakash GabaHorizon: NA (inferred Intraday)10 Aug 2026, 8:49 am ISTvia CNBC Awaaz.

Entry₹1,668Inferred

Target₹1,680

Total upside +0.72%

Stop loss₹1,640-1.68% risk

Exit₹1,64010 Aug 2026, 1:38 pm

Stop-loss hit-1.68%

Follow Prakash Gaba for new calls(20% target hit, 382 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 10 Aug 2026

8 supporting2 neutral0 opposing

Supports the BUY call (8)

1 other SEBI-registered advisor has an active intraday BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·10 Aug · today

4 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·7 Aug · 2d ago

Aurobindo Pharma Shares Tumble 2% Despite Q1 Profit Jump, Double Digit Revenue Guidance For FY27

NewsNdtv-Profit·6 Aug · 4d ago

Aurobindo Pharma's Q1 Margin Story Improves; Macquarie Says Growth Picture Is Still Uneven

NewsNdtv-Profit·6 Aug · 4d ago

Aurobindo Pharma Q1 Results: Profit, EBITDA beat estimates on strong global demand

NewsCnbc-Tv18·5 Aug · 4d ago

Neutral / worth noting (2)

Aurobindo Pharma has announced its unaudited financial results for the first quarter ended June 30, 2026. The company has provided a press release detailing these results.

NSE · Press Release·5 Aug · 4d ago

Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · 4d ago

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Prakash Gaba

Every call and its outcome